Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis

Allergopharma

Status and phase: Completed; Phase 3

Conditions: Allergy

Treatments: Biological: Recombinant grass pollen

Study type: Interventional

Funder types: Industry

Identifiers

NCT00309036

Al0403rP

Details and patient eligibility

About

The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive Skin Prick Test reaction to grass pollen
• Positive RAST result to grass pollen
• Positive Provocation Test result to grass pollen

Exclusion criteria

• Serious chronic diseases
• Other relevant perennial allergies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind